|argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February ...
|argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Revie...
|argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Su...
|argenx Highlights 2024 Strategic Priorities
|argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference